AstraZeneca stock gains as CEO share purchase and EU drug opinions support valuation

AstraZeneca stock (ISIN GB0009895292) closed at 122.85 GBP on the London Stock Exchange on September 17, 2026, leaving the shares 21.9% below a 52-week high of 157.30 GBP and above a 52-week low of 107.84 GBP, according to a recent London price overview dated September 17, 2026.

CEO share purchase and EU opinions set the tone

According to StockTitan, AstraZeneca disclosed that Chief Executive Officer Pascal Soriot bought 60,000 ordinary shares of AstraZeneca PLC on September 14, 2026 at a price of 121.02 GBP per share on the London market, a move that signals confidence in the company’s prospects.

As Yahoo Finance UK reported on September 18, 2026, the European Medicines Agency’s Committee for Medicinal Products for Human Use issued a positive recommendation to extend the indication for Enhertu, developed with Daiichi Sankyo, to adjuvant treatment of patients with residual HER2-positive early breast cancer after neoadjuvant therapy, and also recommended approval of Alexion’s Klygefa for generalized myasthenia gravis.

These EU opinions add to AstraZeneca’s pipeline momentum, and they arrive as the stock is trading materially below its 52-week high, offering investors a combination of regulatory catalysts and a valuation gap versus past price levels.

Stock performance and valuation signals

Per a price overview cited in recent coverage, AstraZeneca shares closed at 122.85 GBP in London on September 17, 2026, which left the stock 21.9 percent below the 52-week high of 157.30 GBP and above the 52-week low of 107.84 GBP, placing the shares in the middle of their yearly trading band.

Intraday data from the London session on September 18, 2026 showed AstraZeneca trading around 125.23 GBP, about 2.0 percent above the prior close of 122.85 GBP, indicating a moderate positive reaction as investors digested the CEO’s share purchase and the latest EU regulatory opinions.

On the US market, AstraZeneca’s American depositary shares traded around 166.13 USD as of the latest New York closing snapshot, with GuruFocus estimating a GF Value of 182.41 USD per share, implying that the US line is roughly 8.9 percent below that intrinsic value measure and suggesting an attractive valuation backdrop relative to this proprietary metric, as highlighted by GuruFocus.

Fundamentals, dividends and risk view

According to recent valuation and dividend analysis by GuruFocus on September 18, 2026, AstraZeneca offers a dividend yield of about 1.93 percent with a payout ratio near 47 percent and a three-year dividend growth rate of 0.2 percent, indicating a modest but sustainable income profile supported by ongoing earnings.

The same analysis notes that AstraZeneca’s trailing price-earnings ratio stands around 24.8, below a five-year median near 33.5, which points to a valuation that is discounted versus the company’s recent earnings multiples and aligns with the GF Value indication that the shares are trading below estimated fair value.

While the EU CHMP’s positive opinions on Enhertu and Klygefa underline strength in oncology and rare disease franchises, risk factors remain, including competition from other biologics, pricing pressures in major markets and the need for continued clinical success across a broad pipeline, as discussed by Zacks, which currently assigns AstraZeneca a Rank 5 (Strong Sell) due to recent setbacks and relative underperformance.

Stock level and investor takeaway

As of the latest completed London session on September 17, 2026, AstraZeneca stock traded at 122.85 GBP on the London Stock Exchange, clearly below the 52-week high of 157.30 GBP yet above the 52-week low of 107.84 GBP, a range that leaves room for upside if regulatory approvals translate into sustained revenue growth while reminding investors of the execution and pricing risks that accompany a large, diversified biopharmaceutical pipeline.

More news and analyses on AstraZeneca stock